Financial Performance - The company's operating revenue for Q1 2025 was CNY 106,736,382.81, a decrease of 0.60% compared to CNY 107,382,466.51 in the same period last year[3] - Net profit attributable to shareholders increased by 102.90% to CNY 28,284,392.84 from CNY 13,940,028.65 year-on-year[3] - The net profit after deducting non-recurring gains and losses rose by 113.63% to CNY 17,505,638.85, compared to CNY 8,194,191.46 in the previous year[3] - Basic earnings per share increased by 133.33% to CNY 0.07 from CNY 0.03 year-on-year[5] - Operating profit for Q1 2025 increased to CNY 31.19 million, up 115.5% from CNY 14.50 million in Q1 2024[17] - Net profit for Q1 2025 reached CNY 27.78 million, representing a 99.5% increase from CNY 13.91 million in Q1 2024[17] - The total comprehensive income attributable to the parent company's owners for Q1 2025 was CNY 31,802,078.64, compared to CNY 13,872,575.70 in Q1 2024, representing a significant increase[18] Cash Flow - The net cash flow from operating activities was CNY 67,703,013.64, reflecting a 65.67% increase from CNY 40,865,611.68 in the same period last year[3] - Cash inflow from operating activities totaled CNY 152,074,084.77 in Q1 2025, an increase from CNY 119,226,178.01 in Q1 2024, marking a rise of 27.55%[18] - Cash outflow from operating activities was CNY 84,371,071.13 in Q1 2025, compared to CNY 78,360,566.33 in Q1 2024, which is an increase of 7.66%[18] - The net cash flow from investing activities for Q1 2025 was -CNY 27,265,973.12, a decrease from CNY 56,428,214.18 in Q1 2024[19] - Cash inflow from investing activities in Q1 2025 was CNY 584,471,684.37, while cash outflow was CNY 27,265,973.12, indicating a net cash outflow[19] - Cash flow from financing activities generated a net inflow of CNY 2,309,134.87 in Q1 2025, compared to a net outflow of -CNY 3,035,925.21 in Q1 2024[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,809,160,583.98, a 3.00% increase from CNY 1,756,516,608.11 at the end of the previous year[5] - Total liabilities increased to CNY 355.39 million, up from CNY 334.04 million year-over-year[15] - The company reported cash and cash equivalents of ¥505,600,712.38 as of March 31, 2025, an increase from ¥462,184,981.34 at the end of December 2024[13] - The ending balance of cash and cash equivalents as of Q1 2025 was CNY 505,237,993.26, up from CNY 467,109,403.98 in Q1 2024, showing an increase of 8.06%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,254[9] - The largest shareholder, JIN LI, holds 81,876,948 shares, representing 20.43% of total shares[10] - The second-largest shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Device Co., Ltd., holds 46,770,579 shares, accounting for 11.67%[10] - There are no significant changes in the shareholder structure or relationships among the top shareholders[10] Research and Development - Research and development expenses totaled CNY 12,824,415.49, accounting for 12.02% of operating revenue, a slight decrease from 12.10% in the previous year[5] - Research and development expenses for Q1 2025 were CNY 12.82 million, slightly down from CNY 12.99 million in Q1 2024[17] Other Income and Gains - The company reported a significant increase in other income to CNY 7.86 million, compared to CNY 1.57 million in the previous year[17] - Government subsidies increased year-on-year, contributing to the significant rise in net profit attributable to shareholders[7] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2025[20] Revenue Analysis - The company attributed the decline in operating revenue primarily to reduced milestone income from its UK subsidiary Vernalis (R&D) Limited, while excluding this, the group experienced an 8% year-on-year growth[7]

Financial Performance - The company's revenue for 2024 reached ¥426,986,937.69, representing a 14.99% increase compared to ¥371,324,936.81 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥51,357,102.96, up 26.13% from ¥40,718,459.76 in 2023[23]. - The net profit after deducting non-recurring gains and losses surged to ¥57,437,228.52, a significant increase of 1,563.94% from ¥3,451,870.89 in 2023[23]. - The net cash flow from operating activities for 2024 was ¥128,009,864.16, a slight increase of 2.24% from ¥125,208,580.35 in 2023[23]. - The total assets at the end of 2024 were ¥1,756,516,608.11, reflecting a 1.56% increase from ¥1,729,558,879.03 at the end of 2023[23]. - The net assets attributable to shareholders increased to ¥1,393,046,074.81, marking a 2.57% rise from ¥1,358,124,788.21 in 2023[23]. - Basic earnings per share for 2024 were ¥0.13, a 30.00% increase from ¥0.10 in 2023[24]. - The diluted earnings per share also stood at ¥0.13, consistent with the basic earnings per share[24]. - The weighted average return on net assets for 2024 was 3.74%, an increase of 0.65 percentage points from 3.09% in 2023[24]. - The company reported a significant increase in the weighted average return on net assets after deducting non-recurring gains and losses, reaching 4.18% compared to 0.26% in 2023[24]. Research and Development - The company is investing in the research and development of new drugs using structure-based drug design (SBDD) and fragment-based drug design (FBDD) methodologies[14]. - The company aims to achieve a 20% reduction in R&D costs through improved operational efficiencies and strategic partnerships[14]. - The R&D expense as a percentage of operating revenue decreased by 5.67 percentage points to 15.77%[25]. - The company reported a total R&D expenditure of ¥67,328,083.61, a decrease of 15.43% compared to the previous year[126]. - R&D expenditure accounted for 15.77% of the company's operating revenue, down from 21.44%, representing a reduction of 5.67 percentage points[126]. - The number of R&D personnel increased to 406, representing 84.06% of the total workforce, compared to 374 and 82.74% in the previous period[133]. - The average salary for R&D personnel decreased to 26.82万元 from 29.43万元 in the previous period[133]. - The company has developed a DNA-encoded compound library (DEL) with over 12 trillion small molecules, making it one of the largest in the world[134]. - The company has established a nucleic acid drug research platform with expertise in bioinformatics, nucleic acid chemistry, RNA biology, and translational research, enhancing its capabilities in RNAi technology services and siRNA/saRNA design and synthesis[141]. Market Strategy and Growth - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[14]. - The company plans to expand its market presence in Asia, targeting a 30% increase in market share over the next two years[14]. - The company has initiated discussions for potential mergers and acquisitions to enhance its product portfolio and market reach[14]. - The company is focusing on its self-developed pipeline projects, adjusting its strategy based on operational cash flow balance considerations[112]. - The company is actively developing the domestic market and has established a dedicated business development team, but faces risks from high customer concentration and potential unmet demand[153]. Technology and Innovation - The company is focusing on the development of DNA-encoded compound libraries (DEL) and high-throughput screening (HTS) technologies to enhance drug discovery efficiency[13]. - The company has established a global DEL alliance with major pharmaceutical companies to enhance drug discovery processes[35]. - The DEL technology allows for the rapid identification of novel lead compounds, even for challenging targets, and is expected to contribute significantly to new drug projects entering clinical trials in the next 5-10 years[74]. - The integration of DEL technology with other drug discovery methods like FBDD and CADD is expected to enhance the overall efficiency and effectiveness of the drug discovery process[74]. - The company has successfully utilized DEL technology to design and synthesize PROTAC molecules, contributing to advancements in the protein degradation field[84]. - The company has developed focused compound libraries to optimize compounds based on specific project requirements, resulting in faster screening speeds and lower costs compared to traditional drug chemistry optimization[82]. Risks and Challenges - The company faces risks related to new drug development failures, particularly as it targets novel molecular entities, which have a higher failure rate compared to improved or generic drugs[151]. - The company is subject to macroeconomic risks, including changes in laws and regulations in foreign markets, which could affect its global operations[156]. - The company operates in a competitive environment with increasing pressure from both domestic and international biotech firms entering the DNA-encoded library technology space[155]. - The company's revenue is heavily dependent on the R&D investment levels of its clients, primarily multinational pharmaceutical companies, which could impact its business if overall R&D spending declines[155]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not experienced any significant changes in governance arrangements or other important matters[8]. - The company did not engage in any equity transfers of new drug projects during the reporting period, indicating a focus on internal development[168]. Investment and Financial Position - The total investment during the reporting period was ¥13,210,185.75, an increase of 3.28% compared to ¥12,791,160.00 in the same period last year[194]. - The company has committed to invest ¥800,000,000.00 in the Chengdu Rongchuang Fund, holding a 40% stake[195]. - The company has recognized a loss of ¥4,575,184.11 from other non-current financial assets during the reporting period[197]. - The company has a total of 17 projects under investment in the biopharmaceutical sector, with a cumulative profit impact of -119.49[199].

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于 成都先导药物开发股份有限公司 2021 年限制性股票激励计划剩余限制性股票作废事项 之 法律意见书 二零二五年四月 关于成都先导药物开发股份有限公司 2021 年限制性股票激励计划剩余限制性股票作废事项 之法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）为在四川省司法厅注册 设立并依法执业的律师事务所。 本所受成都先导药物开发股份有限公司（以下简称"公司""上市公司"或 "成都先导"）的委托，担任成都先导 2021 年限制性股票激励计划（以下简称 "本次激励计划"）的专项法律顾问，依据《中华人民共和国公司法》（以下简 称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市 公司股权激励管理办法》（以下简称《管理办法》）、《上海证券交易所科创板 股票上市规则》（以下简称《上市规则》）、《科创板上市公司自律监管指南第 4 号 ...

成都先导药物开发股份有限公司 募集资金存放与实际使用情况的 专项报告及审核报告 截至 2024 年 12 月 31 日止 Deloitte. 审核报告 德师报(核)字(25)第E00374号 (第1页,共2页) 成都先导药物开发股份有限公司全体股东: 我们审核了后附的成都先导药物开发股份有限公司(以下简称"成都先导公司")截至 2024 年 12月 31 日止募集资金存放与实际使用情况的专项报告(以下简称"募集资金存放与实际使用 情况报告")。 德师报(核)字(25)第E00374号 (第2页,共2页) 三、审核意见 我们认为,成都先导公司的募集资金存放与实际使用情况报告按照中国证券监督管理委员 会《上市公司监管指引第 2 号 -- 上市公司募集资金管理和使用的监管要求》及《上海证券交 易所科创板上市公司自律监管指引第 1 号 -- 规范运作》的规定编制,在所有重大方面真实反 映了成都先导公司截至 2024年12月 31 日止募集资金的存放与实际使用情况。 四、本报告的使用范围 一、董事会对募集资金存放与实际使用情况报告的责任 按照中国证券监督管理委员会《上市公司监管指引第 2 号 -- 上市公司募集资金管理 ...

关于成都先导药物开发股份有限公司 控股股东、实际控制人及其他关联方资金占用情况的专项说明 德师报(函)字(25)第 Q00172 号 成都先导药物开发股份有限公司董事会: 我们接受委托,依据中国注册会计师审计准则审计了成都先导药物开发股份有限公司(以 下简称"贵公司")2024年 12月 31 日合并及母公司资产负债表,2024年度合并及母公司利润 表、合并及母公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注(以下合 称"财务报表"),并于 2025年 4 月 24 日签发了德师报(审)字(25)第 P01882 号无保留意见的审 计报告。 成都先导药物开发股份有限公司 控股股东、实际控制人及其他关联方 资金占用情况的专项说明 2024 年 12 月 31 日止年度 发股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况: | 7 6 | 张 | WHAT THE WANT I WAS FI | | 1275 | I | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

使用部分暂时闲置募集资金进行现金管理的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为成 都先导药物开发股份有限公司（以下简称"成都先导"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等法律、行政法规、部门规章及业务规则， 对成都先导拟使用部分暂时闲置募集资金进行现金管理的事项进行了认真、审 慎的核查，核查情况如下： 一、本次募集资金基本情况 根据中国证券监督管理委员会于 2020 年 3 月 17 日出具的《关于同意成都先 导药物开发股份有限公司首次公开发行股票注册的批复》（证监许可[2020]429 号），公司获准向社会公开发行人民币普通股 40,680,000 股，每股发行价格为 人民币 20.52 元，募集资金总额为人民币 834,753,600.00 元；扣除发行费用人民 币 88,742,433.84元后，实际募集资金净额为人民币 746,011,1 ...

成都先导药物开发股份有限公司 审计报告 德师报(审)字(25)第 P01882 号 (第1页,共6页) 成都先导药物开发股份有限公司全体股东: 一、审计意见 财务报表及审计报告 2024 年 12 月 31 日止年度 | 内容 | 页码 | | | --- | --- | --- | | 审计报告 | 1 - | 6 | | 合并及母公司资产负债表 | 7 - | 10 | | 合并及母公司利润表 | 11 - | 12 | | 合并及母公司现金流量表 | 13 - | 14 | | 合并及母公司股东权益变动表 | 15 - | 16 | | 财务报表附注 | 17 - | 106 | Deloitte. 六十四章タ丘所 (片及边治人) 财务报表及审计报告 2024 年 12 月 31 日止年度 成都先导药物开发股份有限公司 我们审计了成都先导药物开发股份有限公司(以下简称"成都先导公司")的财务报表,包括 2024年12月31日的合并及母公司资产负债表,2024年度的合并及母公司利润表、合并及母公 司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业 ...

中国国际金融股份有限公司 关于成都先导药物开发股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为 成都先导药物开发股份有限公司（以下简称"成都先导"或"公司"）首次公开 发行股票并在科创板上市及持续督导的保荐机构，根据《上市公司监管指引第2 号——上市公司募集资金管理和使用的监管要求》《证券发行上市保荐业务管理 办法》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》《上 海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11号——持续督导》等有关法律法规和规范性文件的要求，中金公司及其指定保 荐代表人对成都先导2024年度募集资金存放与使用情况进行了专项核查，核查情 况与意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可[2020]429 号文《关于同意成都先导药 物开发股份有限公司首次公开发行股票注册的批复》同意，公司于 2020 年 4 月 16 日在上海证券交易所以每股人民币 20.52 元的价格公开发行 40,680,000 股人 ...